Effects of propofol on early and late cytokines in lipopolysaccharide- induced septic shock in rats

Journal of Biomedical Research

Volumn 24, Issue 5, 2010, Pages 389-394

  Li, Sha ^a   Bao, Hongguang ^a   Han, Liu ^a   Liu, Lele ^a  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

High mobility group box 1; Interleukin 6; Propofol; Sepsis; Tumor necrosis factor

Indexed keywords

CYTOKINE; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROPOFOL; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG MECHANISM; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMORAL VEIN; HEART RATE; HEMODYNAMICS; MALE; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INDUCTION; RAT; SEPSIS; SEPTIC SHOCK; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 79952711143     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1674-8301(10)60052-8     Document Type: Article

References (31)

1. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-54.
2. Wyncoll LA, Evans TW. Acute respiratory distress syndrome. Lancet 1999; 354:497-501.
3. Opal SM, Fisher CJ Jr, Dhainaut JF, Vincent JL, Brase R, Lowry SF, et al. Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo controlled, multicenter trial. Crit Care Med 1997;25:1115-24.
4. Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 1995;273:934-41.
5. Wang H, Yang H, Tracey KJ. HMGB1 as a late mediator of lethal systemic inflammation. Am J Respir Crit Care Med 2001;164:1768-73.
6. Bustin M. Regulation of DNA dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19:5237-46.
7. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-1 as a late mediator of endotoxin lethality in mice. Science 1999;285:248-51.
8. Wang H, Vishnubhakat JM, Tracey KJ, Zhang M, Ombrellino M, Sama A, et al. Proinflammatory cytokines(tumor necrosis factor and interleukin 1) stimulate release of high mobility group protein-1 by pituicytes. Surgery 1999;126:389-92.
9. Nimmo GR, Mackenzie SJ, Grant IS. Hemodynamic and oxygen transport effects of propofol infusion in critically ill adults. Anaesthesia 1994;4:485-9.
10. Steinbacher DM. Propofol: a sedative-hypnotic anesthetic agent for use in ambulatory procedures. Anesth Prog 2001;48:66-71.
11. Booke M, Armstrong C, Hinder F, Conroy B, Traber LD, Traber DL. The effects of propofol on hemodynamics and renal blood flow in healthy and in septic sheep, and combined with fentanyl in septic sheep. Anesth Analg 1996; 82:738-43.
12. Takemoto Y. Dose effects of propofol on hemodynamic and cytokine responses to endotoxemia in rats. J Anesth 2005; 19:40-4.
13. Hsu BG, Yang FL, Lee RP, Peng TC, Chen HI. Effects of post-treatment with low-dose propofol on inflammatory responses to lipopolysaccharide-induced shock in conscious rats. Clin Exp Pharmacol Physiol 2005;32:24-9.
14. Taniguchi T, Yamamoto K, Ohmoto N, Ohta K, Kobayashi T. Effects of propofol on hemodynamic and inflammatory responses to endotoxemia in rats. Crit Care Med 2000;28:1101-6.
15. Marik PE. Propofol: therapeutic indications and side-effects. Curr Pharm Des 2004;10:3639-49.
16. Taniguchi T, Kanakura H, Takemoto Y, Kidani Y, Yamamoto K. Effects of ketamine and propofol on the ratio of interleukin-6 to interleukin-10 during endotoxemia in rats. Tohoku J Exp Med 2003;200:85-92.
17. Takao Y, Mikawa K, Nishina K, Obara H. Attenuation of acute lung injury with propofol in endotoxemia. Anesth Analg 2005; 100:810-6.
18. Taniguchi T, Yamamoto K. Anti-inflammatory effects of intravenous anesthetics on endotoxemia. Mini Rev Med Chem 2005;5:241-5.
19. Kuhns DB, Alvord WG, Gallin JI. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in human. J Infect Dis 1995;171:145-52.
20. Damas P, Reuter A, Gysen P, Demonty J, Lamy M, Franchimont P. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.
21. Remick DG, Bolgos GR, Siddiqui J, Shin J, Nemzek JA. Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days. Shock 2002;17:463-7.
22. Yang H, Tracey KJ. Targeting HMGB1 in inflammation. Biochim Biophys Acta 2010;1799:149-56.
23. Andersson U, Wang H, Palmblad K, Aveberger AC, Bloom O, Erlandsson-Harris H, et al. High mobility group 1 protein (HMGB1) stimulates proinflammatory cytokine synthesis in human monocytes. J Exp Med, 2000;192: 565-70.
24. Song XM, Wang YL, Li JG, Wang CY, Zhou Q, Zhang ZZ, et al. Effects of propofol on pro-inflammatory cytokines and nuclear factor kappaB during polymicrobial sepsis in rats. Mol Biol Rep 2009;36:2345-51.
25. Gordon BR, Parker TS, Levine DM, Saal SD, Wang JC, Sloan BJ, et al. Low lipid concentrations in critical illness: Implications for preventing and treating endotoxemia. Crit Care Med 1996;24:584-9.
26. Cavaillon JM, Fitting C, Haeffner-Cavaillon N, Kirsch SJ, Warren HS. Cytokine response by monocytes and macrophages to free and lipoprotein-bound lipopolysaccharide. Infect Immun 1990;58:2375-82.
27. Hubsch AP, Powell FS, Lerch PG, Doran JE. A reconstituted, apolipoprotein A-I containing lipoprotein reduces tumor necrosis factor release and attenuates shock in endotoxemic rabbits. Circ Shock 1993;40:14-23.
28. Harris HW, Grunfeld C, Feingold KR, Read TE, Kane JP, Jones AL, et al. Chylomicrons alter the fate of endotoxin, decreasing tumor necrosis factor release and preventing death. J Clin Invest 1993;91:1028-34.
29. Levine DM, Parker TS, Donnelly TM, Walsh A, Rubin AL. In vivo protection against endotoxin by plasma high density lipoprotein. Proc Natl Acad Sci U S A 1993; 90:12040-4.
30. Tobias PS, Ulevitch RJ. Control of lipopolysaccharide-high density lipoprotein binding by acute phase protein(s). J Immunol 1983;131:1913-6.
31. Pan QJ, Liu Y, Zheng J, Lu X, Wu S, Zhu P, et al. Protective effect of chloral hydrate against lipopolysaccharide/D-galactosamine-induced acute lethal liver injury and zymosan-induced peritonitis in mice. Int Immunopharmacol 2010;10:967-77.